Vintura ads

⏱️𝗘𝗮𝗿𝗹𝗶𝗲𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀 𝗶𝗻 𝗔𝗠𝗟: 𝘄𝗵𝘆 𝗠𝗥𝗗 𝗱𝗲𝘀𝗲𝗿𝘃𝗲𝘀 𝗮𝘁𝘁𝗲𝗻𝘁𝗶𝗼𝗻 This paper synthesizes perspectives from clinicians, payers, and patient advocacy groups, and establishes a roadmap for future priorities in AML clinical development. Reliance on overall survival continues as the primary endpoint prolongs AML (acute myeloid leukemia) drug development timelines, delaying patient access to new effective therapies. Yet patient perspectives in AML are still underrepresented in regulatory and HTA decision‑making. ⚖️💊 Waiting for long‑term outcomes of new therapies delays patient access. For patients with AML, that often means months – or even years – of uncertainty. MRD (measurable residual disease) testing can help close this gap. It detects small traces of disease. It offers earlier insight into how well a therapy is working – long before overall survival data are available. Many stakeholders recognize MRD’s potential for better clinical decisions, clearer next steps, and more proactive disease monitoring. However, MRD testing methods differ and assessment timings vary. ⚠️ 𝗪𝗵𝗮𝘁 𝗻𝗲𝗲𝗱𝘀 𝘁𝗼 𝗵𝗮𝗽𝗽𝗲𝗻 𝗻𝗲𝘅𝘁? 1. 𝗘𝗻𝗴𝗮𝗴𝗲 𝗮𝗻𝗱 𝗲𝗱𝘂𝗰𝗮𝘁𝗲 𝘀𝘁𝗮𝗸𝗲𝗵𝗼𝗹𝗱𝗲𝗿𝘀 – Build awareness across patients, clinicians, regulators, payers, and advocacy groups on the value of MRD. 2. 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝗶𝘇𝗲 𝗠𝗥𝗗 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁𝘀 – Align on thresholds, timepoints, and assessment guidelines to ensure consistent testing and data. 3. 𝗦𝘆𝘀𝘁𝗲𝗺𝗮𝘁𝗶𝘇𝗲 𝗠𝗥𝗗 𝘂𝘀𝗲 𝗴𝗹𝗼𝗯𝗮𝗹𝗹𝘆 – Apply standardized measurement, reporting, and agreed clinical thresholds to strengthen data quality and adoption. 4. 𝗟𝗶𝗻𝗸 𝗠𝗥𝗗 𝘁𝗼 𝗢𝗦 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 – Integrate MRD with OS as (co-)endpoints in trials and RWE to accelerate uptake in trial design. #MPAACT is an industry‑led research consortium, established in 2021, focused on evaluating MRD as a surrogate endpoint for overall survival in AML and generating robust, aligned MRD data. Vintura supports this effort through multi‑stakeholder engagements with key experts and a patient representative from the EU and the US. 📖 Read the open‑access publications: https://lnkd.in/e6qvktyi and https://lnkd.in/dXSi65iq 💬 𝗝𝗼𝗶𝗻 𝘁𝗵𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻: What role should MRD play in AML drug approvals and HTA decisions? #AML #MRD #PatientOutcomes #CancerCare #ClinicalTrials

This paper synthesizes perspectives from clinicians, payers, and patient advocacy groups, and establishes a roadmap for future priorities in AML clinical development. MPAACT is an industry‑led research consortium, established in 2021, focused on evaluating MRD as a surrogate endpoint for overall survival in AML and generating robust, aligned MRD data. Vintura supports this effort through multi‑stakeholder engagements with key experts and a patient representative from the EU and the US. Read the open access publications: https://lnkd.in/e6qvktyi and https://lnkd.in/eB8BCN42

This paper synthesizes perspectives from clinicians, payers, and patient advocacy groups, and establishes a roadmap for future priorities in AML clinical development. MPAACT is an industry led research consortium, established in 2021, focused on evaluating MRD as a surrogate endpoint for overall survival in AML and generating robust, aligned MRD data. Vintura supports this effort through multi stakeholder engagements with key experts and a patient representative from the EU and the US. Read the open access publications: https://lnkd.in/eB8BCN42 and https://lnkd.in/e6qvktyi

🔬 𝗛𝗼𝘄 𝗰𝗮𝗻 𝘄𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗱𝗿𝘂𝗴𝘀 𝗳𝗮𝘀𝘁𝗲𝗿 𝗶𝗻 𝗔𝗠𝗟: 𝗠𝗥𝗗 𝗮𝘀 𝘀𝘂𝗿𝗿𝗼𝗴𝗮𝘁𝗲 𝗳𝗼𝗿 𝗢𝗦 This paper synthesizes perspectives from clinicians, payers, and patient advocacy groups, and establishes a roadmap for future priorities in AML clinical development. AML (acute myeloid leukemia) necessitates extended clinical development follow-up due to its complex natural disease history. Relying on overall survival delays evidence generation and limits timely patient access to new therapies. 🚧 MRD (measurable residual disease) is a strong prognostic marker in AML and provides sensitive and early insights into response. MRD can speed up evidence generation, support early decision-making, and enable timely access to new therapies. However, differences in MRD definitions, methods, and timing, together with limited trial‑level correlation of MRD and overall survival, impedes cross-trial comparability and limits #regulatory and #HTA acceptance. ⚠️ 𝗞𝗲𝘆 𝗮𝗰𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻 𝗠𝗥𝗗’𝘀 𝗿𝗼𝗹𝗲 𝗶𝗻 𝗔𝗠𝗟 𝗶𝗻𝗰𝗹𝘂𝗱𝗲: 1. 𝗘𝗻𝗴𝗮𝗴𝗲 𝗮𝗻𝗱 𝗲𝗱𝘂𝗰𝗮𝘁𝗲 𝘀𝘁𝗮𝗸𝗲𝗵𝗼𝗹𝗱𝗲𝗿𝘀 – Build awareness across patients, clinicians, regulators, payers, and advocacy groups on the value of MRD. 2. 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝗶𝘇𝗲 𝗠𝗥𝗗 𝗮𝘀𝘀𝗲𝘀𝘀𝗺𝗲𝗻𝘁𝘀 – Align on thresholds, timepoints, and assessment guidelines to ensure consistent testing and data. 3. 𝗦𝘆𝘀𝘁𝗲𝗺𝗮𝘁𝗶𝘇𝗲 𝗠𝗥𝗗 𝘂𝘀𝗲 𝗴𝗹𝗼𝗯𝗮𝗹𝗹𝘆 – Apply standardized measurement, reporting, and agreed clinical thresholds to strengthen data quality and adoption. 4. 𝗟𝗶𝗻𝗸 𝗠𝗥𝗗 𝘁𝗼 𝗢𝗦 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 – Integrate MRD with OS as (co-)endpoints in trials and RWE to accelerate uptake in trial design. #MPAACT is an industry‑led research consortium, established in 2021, focused on evaluating MRD as a surrogate endpoint for overall survival in AML and generating robust, aligned MRD data. Vintura supports this effort through multi‑stakeholder engagements with key experts and a patient representative from the EU and the US. 📖 Read the open‑access publications: https://lnkd.in/e6qvktyi and https://lnkd.in/dXSi65iq 💬 𝗝𝗼𝗶𝗻 𝘁𝗵𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻: How do we move MRD from potential to acceptance? #AML #MRD #ValueBasedHealthcare #EvidenceGeneration #OncologyPolicy

This paper synthesizes perspectives from clinicians, payers, and patient advocacy groups, and establishes a roadmap for future priorities in AML clinical development. MPAACT is an industry led research consortium, established in 2021, focused on evaluating MRD as a surrogate endpoint for overall survival in AML and generating robust, aligned MRD data. Vintura supports this effort through multi stakeholder engagements with key experts and a patient representative from the EU and the US. Read the open access publications: https://lnkd.in/e6qvktyi and https://lnkd.in/eB8BCN42

Algemeen Dagblad vroeg naar mijn visie vanuit Vintura over de vastgelopen samenwerking in Zeeland. ▫️Het is een ‘logische reflex’ bij ziekenhuizen om zo veel mogelijk zorg in eigen huis te willen houden, maar dat wordt steeds lastiger ▫️Samenwerken om complexe zorg te concentreren is onvermijdelijk, maar leidt tot discussies met rationale overwegingen en emoties ▫️Dat de ziekenhuizen de samenwerking hebben opgeschort, kan komen omdat de urgentie toch niet groot genoeg is ▫️De oproep van de verzekeraar om over de eigen schaduw heen te stappen, is zo gek nog niet ▫️Dit sluit aan bij de gedachte achter de Zeeuwse Zorg Coalitie: samen proberen zo veel mogelijk zorg te behouden voor de regio en als het complexer wordt wat verder weg 📰 Zie hier het artikel: https://lnkd.in/e48JrmVZ 🗞️En de link naar AD: https://lnkd.in/eKtym9Gi Met dank aan Rolf Bosboom, Melanie Knieriem, Jessie Eerens - Fourie en Aart Willem Saly.